Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Cancer × tilsotolimod × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 4 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Skin Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Squamous Cell 1 Advanced Cancer 1

Interventions

Nivolumab 15 Ipilimumab 7 linrodostat 5 Standard of Care 5 Paclitaxel 5 Bevacizumab 5 temsirolimus 4 Sirolimus 4 Gemcitabine 4 Docetaxel 4 relatlimab 3 Vorinostat 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Cetuximab 3 Carboplatin 3 ARRY-334543 3 regorafenib 2 apatinib 2 abemaciclib 2 Trastuzumab 2 Surveys and Questionnaires 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2 Interviews as Topic 2 Everolimus 2 Dasatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04270864 2024-10-18

PRIMO

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Terminated

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡